Table 2.

Characteristics of RCTs included in the systematic review

Study, YearCountrySample SizeMean AgeStage of CKDBaseline 25(OH)D/ PTH Level (mean)InterventionStudy Duration (months)Outcomes Reported
Chandra, 2008 (24)United States20613 and 420/36850,000 IU of cholecalciferol or placebo once weekly325(OH)D, 1,25(OH)2Da PTH, calcium, phosphorus
Dogan, 2008 (25)Turkey40493 to 48.5/368300,000 IU cholecalciferol versus placebo in a single dose orally125(OH)D, PTH, calcium, phosphorus
Oksa, 2008 (23)Slovakia87662 to 419.5/68.3Oral cholecalciferol 5000 IU/wk (group A) or 20,000 IU/wk (group B)1225(OH)D, 1,25(OH)2D PTH, calcium, phosphorus
Wissing, 2005 (26)Belgium7943Transplant24.5/127Patients were randomized to receive cholecalciferol (25,000 IU) or no treatment in addition to calcium supplementation.1225(OH)D, 1,25(OH)2D, PTH, calcium, phosphorus
Siebert, 2007 (27)Germany38NAHD11.8/192.3Oral cholecalciferol—dose not mentioned325(OH)D, PTH, calcium, phosphorus
  • Vitamin D levels are shown in ng/ml and PTH levels are shown in pg/ml. HD, hemodialysis; not applicable.

  • ↵a Data were not available.